Can Glenmark Pharmaceuticals’ FDA approval for Enstilar Foam generic boost its U.S. dermatology footprint?

Glenmark Pharmaceuticals has announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. The formulation is a generic version of Enstilar Foam, 0.005%|0.064%, a prescription treatment for plaque psoriasis developed by Denmark-based Leo Pharma. This regulatory milestone is expected to position Glenmark Pharmaceuticals to further strengthen its presence in the U.S. dermatology market once the product achieves commercial launch clearance.

The approval marks another addition to the Indian drugmaker’s growing portfolio of topical dermatology products in the American market, where the company has consistently sought to capture market share through cost-competitive alternatives to branded therapies.

What does the FDA approval for Glenmark’s Enstilar Foam generic mean for the U.S. psoriasis treatment market?

Enstilar Foam is prescribed for the topical treatment of plaque psoriasis in adults, a chronic autoimmune skin condition that causes red, scaly patches. The branded formulation combines two active ingredients—calcipotriene, a vitamin D analog that slows excessive skin cell growth, and betamethasone dipropionate, a corticosteroid that reduces inflammation and itching. By replicating this combination in its generic equivalent, Glenmark Pharmaceuticals is aiming to provide a lower-cost treatment option to patients and healthcare providers without compromising therapeutic efficacy.

According to IQVIA sales data for the 12 months ending March 2022, the Enstilar Foam market generated approximately $115.2 million in annual U.S. sales. This figure underscores the revenue potential available to generic entrants, particularly in a segment where topical foams have gained traction for their ease of application and patient compliance.

Industry analysts have noted that the U.S. generic dermatology space is becoming increasingly competitive, with several multinational and domestic pharmaceutical firms seeking to capture market share as patents on high-value branded formulations expire. In this context, Glenmark Pharmaceuticals’ FDA clearance represents both an opportunity to tap into a sizable revenue pool and a test of its ability to navigate competitive pricing pressures.

How does Glenmark Pharmaceuticals’ U.S. product portfolio position it for dermatology market growth?

As of this approval date, Glenmark Pharmaceuticals’ U.S. portfolio consists of 174 products authorized for distribution, spanning a wide range of therapeutic areas including dermatology, respiratory, oncology, and cardiovascular care. The company also has 48 abbreviated new drug applications (ANDAs) under review with the FDA, reflecting a steady pipeline strategy aimed at sustaining growth in the American generics market.

Dermatology has been a strategic focus for the Mumbai-headquartered drugmaker, which has leveraged its formulation development capabilities to launch topical creams, ointments, gels, and foams that target both chronic and acute skin conditions. With the Enstilar Foam generic, Glenmark Pharmaceuticals adds a branded-equivalent topical treatment with proven demand, reinforcing its dermatology portfolio alongside products for eczema, acne, and other inflammatory skin disorders.

In the U.S., where insurance reimbursement policies increasingly favor generics, portfolio breadth can play a critical role in securing formulary placements with large pharmacy benefit managers (PBMs) and retail pharmacy chains. Glenmark Pharmaceuticals’ expanding dermatology lineup may help strengthen its negotiating position with these stakeholders.

Why does the psoriasis treatment market present a strategic opportunity for generic drugmakers?

Plaque psoriasis affects an estimated 7.5 million Americans, according to the National Psoriasis Foundation, with many patients requiring long-term or lifelong therapy. While systemic biologics and oral treatments have transformed care for moderate-to-severe cases, topical therapies remain a cornerstone for patients with mild-to-moderate disease or localized flare-ups.

The U.S. topical psoriasis market has historically been dominated by branded products from multinational dermatology specialists. However, as patent protections expire, generic manufacturers are increasingly able to enter the segment with bioequivalent formulations. This shift has the potential to reduce treatment costs and expand patient access, a trend that aligns with payer objectives to manage rising dermatology drug expenditures.

For Glenmark Pharmaceuticals, entering this market with an FDA-approved generic of Enstilar Foam allows it to compete in a therapeutic niche with a relatively stable demand base. While pricing competition is expected, established manufacturing capabilities and regulatory compliance history could provide the company with an operational advantage.

What competitive dynamics could shape Glenmark’s U.S. launch of its Enstilar Foam generic?

The timing of commercial launch will depend on market exclusivity periods and patent settlements, factors that often shape the entry strategy for generics. In certain cases, first-to-file generic manufacturers can secure a 180-day exclusivity window, enabling them to capture significant early sales before additional generics enter the market. However, if Glenmark Pharmaceuticals is not the first entrant, it will need to compete on both price and distribution reach to capture meaningful share.

Leo Pharma, the originator of Enstilar Foam, has built strong brand recognition among U.S. dermatologists. Generic penetration in such markets can be gradual if prescribers and patients remain loyal to the branded product, especially when manufacturer discount programs narrow the price gap. Nonetheless, in the long term, payers typically encourage switching to generics to reduce costs, which could favor Glenmark Pharmaceuticals once its product becomes available.

In addition, the dermatology generics segment has seen supply chain pressures in recent years, with raw material availability, manufacturing capacity, and quality compliance all influencing a product’s market success. Glenmark Pharmaceuticals’ ability to maintain consistent supply could be a decisive factor in its competitive positioning.

Could this approval influence Glenmark’s broader U.S. growth strategy?

The U.S. remains Glenmark Pharmaceuticals’ largest revenue contributor among international markets, and the company has consistently invested in expanding its product portfolio to capture new opportunities. In recent years, it has pursued approvals in therapeutic areas with high market value and sustainable demand, ranging from cardiovascular medications to complex generics.

The tentative FDA approval for Calcipotriene and Betamethasone Dipropionate Foam underscores Glenmark Pharmaceuticals’ commitment to building a diversified portfolio that spans both commodity generics and more specialized, high-value treatments. This approach allows the company to balance volume-driven revenue streams with higher-margin niche products.

If successfully commercialized, the Enstilar Foam generic could enhance Glenmark Pharmaceuticals’ dermatology credentials in the U.S., potentially opening doors to further collaborations with dermatology specialists, contract manufacturing opportunities, and expanded research into novel topical delivery systems.

How significant is the FDA approval for Glenmark’s dermatology ambitions?

While the U.S. market launch of Glenmark Pharmaceuticals’ Enstilar Foam generic will depend on regulatory and patent factors, the FDA approval represents a clear step forward in the company’s dermatology growth plan. The psoriasis treatment market offers stable demand, and the $115.2 million annual sales of the branded product provide a sizable revenue target for generic competition.

For patients and healthcare providers, the arrival of a generic alternative could mean more affordable access to an established therapy. For Glenmark Pharmaceuticals, it strengthens its position as a versatile generics manufacturer with a growing dermatology footprint in the U.S. Whether the company can translate this regulatory milestone into sustained market share will depend on launch timing, competitive dynamics, and its ability to maintain supply and quality standards in a highly competitive environment.